Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges

被引：49
作者：
Bakht M.K. [1 ,2 ,3 ]
Oh S.W. [1 ,2 ]
Youn H. [1 ,2 ]
Cheon G.J. [1 ,2 ]
Kwak C. [4 ]
Kang K.W. [1 ,2 ]
机构：
[1] Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul
[2] Laboratory of Molecular Imaging and Therapy, Cancer Research Institute, Seoul National University College of Medicine, Seoul
[3] Department of Biological Sciences, University of Windsor, Windsor, N9B 3P4, ON
[4] Department of Urology, Seoul National University College of Medicine, Seoul
来源：
Nuclear Medicine and Molecular Imaging | 2017年 / 51卷 / 3期
关键词：
Antiandrogens; Molecular imaging; Positron emission tomography; Prostate cancer; Prostate-specific membrane antigen;
D O I：
10.1007/s13139-016-0439-4
中图分类号：
学科分类号：
摘要：
Prostate-specific membrane antigen (PSMA) is an attractive target for both diagnosis and therapy because of its high expression in the vast majority of prostate cancers. Development of small molecules for targeting PSMA is important for molecular imaging and radionuclide therapy of prostate cancer. Recent evidence implies that androgen-deprivation therapy increase PSMA-ligand uptake in some cases. The reported upregulations in PSMA-ligand uptake after exposure to second-generation antiandrogens such as enzalutamide and abiraterone might disturb PSMA-targeted imaging for staging and response monitoring of patients undergoing treatment with antiandrogen-based drugs. On the other hand, second-generation antiandrogens are emerging as potential endoradio-/chemosensitizers. Therefore, the enhancement of the therapeutic efficiency of PSMA-targeted theranostic methods can be listed as a new capability of antiandrogens. In this manuscript, we will present what is currently known about the mechanism of increasing PSMA uptake following exposure to antiandrogens. In addition, we will discuss whether these above-mentioned antiandrogens could play the role of endoradio-/chemosensitizers in combination with the well-established PSMA-targeted methods for pre-targeting of prostate cancer. © 2016, Korean Society of Nuclear Medicine.
引用
收藏
页码：202 / 211
页数：9
相关论文
共 67 条
  • [1] Haas G.P., Delongchamps N., Brawley O.W., Wang C.Y., de la Roza G., The worldwide epidemiology of prostate cancer: perspectives from autopsy studies, Can J Urol, 15, pp. 3866-3871, (2008)
  • [2] Perner S., Cronauer M.V., Schrader A.J., Klocker H., Culig Z., Baniahmad A., Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer, Oncotarget, 29, pp. 35542-35555, (2015)
  • [3] Chandrasekar T., Yang J.C., Gao A.C., Evans C.P., Targeting molecular resistance in castration-resistant prostate cancer, BMC Med, (2015)
  • [4] Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T., Et al., EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 65, pp. 467-479, (2014)
  • [5] Kiess A.P., Banerjee S.R., Mease R.C., Rowe S.P., Rao A., Foss C.A., Et al., Prostate-specific membrane antigen as a target for cancer imaging and therapy, Q J Nucl Med Mol Imaging, 59, pp. 241-268, (2015)
  • [6] Rai B.P., Baum R., Patel A., Hughes R., Alonzi R., Lane T., Et al., The role PET with <sup>68</sup>Gallium (Ga)-labelled prostate-specific membrane antigen (PSMA) in the management of patient with organ confined and locally advanced prostate cancer prior to radical treatment and after radical prostatectomy, Urology, (2016)
  • [7] Ananias H.J., van den Heuvel M.C., Helfrich W., de Jong I.J., Expression of the gastrin‐releasing peptide receptor, the prostate stem cell antigen and the prostate‐specific membrane antigen in lymph node and bone metastases of prostate cancer, Prostate, 69, pp. 1101-1108, (2009)
  • [8] Minner S., Wittmer C., Graefen M., Salomon G., Steuber T., Haese A., Et al., High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer, Prostate, 71, pp. 281-288, (2011)
  • [9] Rybalov M., Ananias H.J., Hoving H.D., van der Poel H.G., Rosati S., de Jong I.J., PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy, Int J Mol Sci, 15, pp. 6046-6061, (2014)
  • [10] Akhtar N.H., Pail O., Saran A., Tyrell L., Tagawa S.T., Prostate-specific membrane antigen-based therapeutics, Adv Urol, (2011)
1234567